Highlights
- Market Cap
- $7.59B
- Enterprise Value
- $7.55B
- EPS (TTM)
- -$0.37
- Total Revenue (TTM)
- $113.29M
- Gross Profit (TTM)
- $112.54M
- EBITDA (TTM)
- -$257.20M
- Year Range
- $1.83 - $12.43
- Target Price
- $11.00
- ROA (TTM)
- -70.01%
- ROE (TTM)
- 70.34%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ImmunityBio, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
ImmunityBio, Inc. (IBRX) has returned 287.37% so far this year and 154.82% over the past 12 months. Over the last ten years, IBRX has returned -1.17% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
ImmunityBio, Inc.
- 1D
- 15.17%
- 1M
- -21.57%
- YTD
- 287.37%
- 6M
- 211.79%
- 1Y
- 154.82%
- 3Y*
- 61.53%
- 5Y*
- -19.29%
- 10Y*
- -1.17%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jul 28, 2015, IBRX's average daily return is +0.18%, while the average monthly return is +3.48%. At this rate, your investment would double in approximately 1.7 years.
Historically, 40% of months were positive and 60% were negative. The best month was Jan 2026 with a return of +215.7%, while the worst month was Dec 2024 at -49.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, IBRX closed higher 45% of trading days. The best single day was Jan 13, 2020 with a return of +91.0%, while the worst single day was May 11, 2023 at -55.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 215.66% | 56.48% | -21.57% | 287.37% | |||||||||
| 2025 | 34.77% | -4.64% | -8.51% | -16.61% | 5.98% | -0.75% | -6.82% | -4.88% | 5.13% | -2.44% | -1.67% | -16.10% | -22.66% |
| 2024 | -33.07% | 40.77% | 13.53% | 48.79% | -19.65% | -1.56% | -18.51% | -23.30% | -5.82% | 40.05% | -3.26% | -49.21% | -49.00% |
| 2023 | -25.05% | -35.79% | -25.41% | 53.85% | -1.79% | 1.09% | -20.86% | -26.82% | 4.97% | 85.80% | 17.20% | 36.41% | -0.99% |
| 2022 | -4.28% | 17.53% | -17.98% | -35.29% | 3.58% | -1.06% | 4.57% | 2.83% | 24.25% | 10.66% | 0.18% | -7.99% | -16.61% |
| 2021 | 41.60% | 72.24% | -26.98% | -25.23% | -1.13% | -18.63% | -23.25% | 3.83% | -14.41% | -19.61% | -0.51% | -21.95% | -54.39% |
Benchmark Metrics
ImmunityBio, Inc. has an annualized alpha of 24.82%, beta of 1.80, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since July 29, 2015.
- This stock participated in 180.14% of S&P 500 Index downside but only 86.46% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 24.82%
- Beta
- 1.80
- R²
- 0.09
- Upside Capture
- 86.46%
- Downside Capture
- 180.14%
Return for Risk
Risk / Return Rank
IBRX ranks 83 for risk / return — in the top 83% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ImmunityBio, Inc. (IBRX) and compare them to a chosen benchmark (S&P 500 Index).
| IBRX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.44 | 0.90 | +0.54 |
Sortino ratioReturn per unit of downside risk | 2.54 | 1.39 | +1.15 |
Omega ratioGain probability vs. loss probability | 1.31 | 1.21 | +0.10 |
Calmar ratioReturn relative to maximum drawdown | 3.40 | 1.40 | +2.00 |
Martin ratioReturn relative to average drawdown | 5.58 | 6.61 | -1.03 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore IBRX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the ImmunityBio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ImmunityBio, Inc. was 97.14%, occurring on Jun 10, 2019. Recovery took 427 trading sessions.
The current ImmunityBio, Inc. drawdown is 81.85%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.14% | Jul 30, 2015 | 972 | Jun 10, 2019 | 427 | Feb 18, 2021 | 1399 |
| -97.03% | Feb 23, 2021 | 670 | Oct 19, 2023 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ImmunityBio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ImmunityBio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IBRX relative to other companies in the Biotechnology industry. Currently, IBRX has a P/S ratio of 63.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |